Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 15 - Press Release Titled Extract of Audited Standalone and Consolidated Financial Results ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Asarfi Hospital Limited, a Dhanbad-based healthcare provider operating two hospitals (super-specialty and oncology), reported strong FY26 results. Revenue grew 42% YoY to ₹173 Cr from ₹121.8 Cr, driven by 46% growth in IPD revenue and 34% growth in OPD revenue. PAT surged 57.5% to ₹16.7 Cr from ₹10.6 Cr, with PAT margin expanding to 10%. EBITDA stood at ₹35.3 Cr with 20% margin. ROCE improved from 14% to 17%, while Debt-to-Equity marginally improved to 0.59x. Growth was led by high-acuity specialties like Cardiology, Neurosciences, and Orthopaedics, along with Radiation Oncology at the cancer unit.
The company delivered robust double-digit revenue and profit growth with margin expansion and improving return metrics, signaling strong operational execution. The stable leverage and rising ROCE indicate healthy financial management, which should be positive for shareholder confidence.